Dyne Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference

Rhea-AI Summary

Dyne Therapeutics (Nasdaq: DYN), a clinical-stage muscle disease company, has announced its participation in Chardan's 8th Annual Genetic Medicines Conference. The event is scheduled to take place in New York on Monday, September 30, 2024. Dyne's management team will engage in a fireside chat at 2:00 p.m. ET.

The company, which focuses on developing innovative life-transforming therapeutics for people with genetically driven diseases, will provide a live webcast of the presentation. Interested parties can access the webcast through the Investors & Media section of Dyne's official website. For those unable to attend the live event, a replay will be available for 90 days following the presentation.

News Market Reaction – DYN

-5.36%

-5.36% Session move

In the trading session that priced this news, DYN declined 5.36%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at Chardan’s 8^th Annual Genetic Medicines Conference being held in New York on Monday, September 30, 2024 at 2:00 p.m. ET.

A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue. Dyne has a broad pipeline for serious muscle diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.

Contact:

Dyne Therapeutics
Amy Reilly
areilly@dyne-tx.com
857-341-1203

FAQ

When and where is Dyne Therapeutics (DYN) presenting at Chardan's Genetic Medicines Conference?

Dyne Therapeutics (DYN) is presenting at Chardan's 8th Annual Genetic Medicines Conference in New York on Monday, September 30, 2024 at 2:00 p.m. ET.

How can I watch Dyne Therapeutics' (DYN) presentation at the Chardan conference?

You can watch a live webcast of Dyne Therapeutics' (DYN) presentation in the Investors & Media section of Dyne's website at https://investors.dyne-tx.com/news-and-events/events-and-presentations.

How long will the replay of Dyne Therapeutics' (DYN) Chardan conference presentation be available?

The replay of Dyne Therapeutics' (DYN) presentation at the Chardan conference will be accessible for 90 days following the live event.

What is the focus of Dyne Therapeutics (DYN) as a company?

Dyne Therapeutics (DYN) is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases.